Suppliers / Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS

Denmark 946 employees 2 duplicate records merged Updated 9 July 2026

Xellia Pharmaceuticals ApS is an API manufacturer based in Denmark. It holds 19 active US drug master files across a filed portfolio of 10 molecules. Its filings concentrate with MPA (SE), EMA and AIFA (IT). Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 28 October 2021 as VAI.

19
active US DMFs
0
valid CEPs
5
registered plants 2 with an FDA FEI number
44
filings across 9 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 28 October 2021 VAI US FDA
  • 25 October 2019 VAI US FDA
  • 8 May 2018 VAI US FDA
  • 6 April 2018 VAI US FDA
  • 15 March 2016 VAI US FDA
  • 26 March 2015 NAI US FDA
  • 6 May 2014 VAI US FDA
  • 16 October 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Kobenhavn S, United Arab Emirates Not on file
China, China 3007422723
COPENHAGEN, Denmark Not on file
Denmark, Denmark 3002806860
Copenhagen S, Denmark Not on file

What they file, and where

Molecule Regulators Docs
Vancomycin SFDA (Saudi Arabia), US FDA 7
Amphotericin B SFDA (Saudi Arabia), US FDA 4
Bacitracin US FDA 4
Colistimethate SFDA (Saudi Arabia), US FDA 3
Daptomycin SFDA (Saudi Arabia), US FDA 3
Gramicidin D SFDA (Saudi Arabia), US FDA 3
Polymyxin B US FDA 2
Tobramycin US FDA 2
Colistin US FDA 1
Dalbavancin US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MPA (SE) 10 None
EMA 10 1
AIFA (IT) 8 None
INFARMED (PT) 5 None
JFDA (JO) 3 None
AEMPS (ES) 2 None

Comparing suppliers?

Choose your molecules and target markets. Xellia Pharmaceuticals ApS comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 6 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 28 October 2021.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates